[Modification of the histopathologic degree of inflammation in asymptomatic prostatitis (NIH IV) by moxifloxacin]

Urologe A. 2007 Sep;46(9):1027-30. doi: 10.1007/s00120-007-1383-9.
[Article in German]
No abstract available

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use*
  • Aza Compounds / adverse effects
  • Aza Compounds / therapeutic use*
  • Biomarkers, Tumor / blood
  • Biopsy
  • Double-Blind Method
  • Fluoroquinolones
  • Humans
  • Male
  • Moxifloxacin
  • Prospective Studies
  • Prostate / drug effects
  • Prostate / pathology
  • Prostate-Specific Antigen / blood
  • Prostatitis / blood
  • Prostatitis / drug therapy*
  • Prostatitis / pathology*
  • Quinolines / adverse effects
  • Quinolines / therapeutic use*

Substances

  • Anti-Infective Agents
  • Aza Compounds
  • Biomarkers, Tumor
  • Fluoroquinolones
  • Quinolines
  • Prostate-Specific Antigen
  • Moxifloxacin